Inhibrx Biosciences/$INBX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Inhibrx Biosciences

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Ticker

$INBX
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
La Jolla, United States

Employees

159

ISIN

US45720N1037
Website
inhibrx.com

INBX Metrics

BasicAdvanced
$332M
0.21
$111.58
-
-

What the Analysts think about INBX

Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.

Bulls say / Bears say

Inhibrx Biosciences reported a net income of $1.69 billion for fiscal year 2024, a significant turnaround from a net loss of $241.4 million in 2023, primarily due to the completion of a spin-off transaction. (GuruFocus)
The company secured a $100 million loan from Oxford Finance LLC in January 2025, with an additional $50 million available at the lender's discretion, enhancing liquidity for ongoing clinical trials. (GuruFocus)
Inhibrx Biosciences has two ongoing clinical trials with data readouts expected within 12 months, indicating potential advancements in their pipeline. (Ainvest)
The company reported a net loss of $47.9 million in Q4 2024, despite the overall annual profit, highlighting ongoing operational challenges. (GuruFocus)
Research and development expenses increased to $203.7 million in 2024 from $191.6 million in 2023, driven by expanded clinical trial activities, which may strain financial resources. (GuruFocus)
General and administrative expenses surged to $127.9 million in 2024 from $29.4 million in 2023, largely due to one-time expenses related to the spin-off transaction and increased legal and pre-commercialization costs. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 15 Jul 2025.

INBX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

INBX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INBX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs